Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View Item
  • Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer.

Thumbnail
View/Open
Supporting information (63.31Kb)
Publication Date
2018-02
ICR Author
Pratt, Brenda
Parker, Chris
Flux, Glenn
Marsden,
Author
Pratt, BE
Hindorf, C
Chittenden, SJ
Parker, CC
Flux, GD
Type
Journal Article
Metadata
Show full item record
Abstract
OBJECTIVE:The aim of the study was to determine the fraction of administered activity that was excreted and retained by a small cohort of patients who each received treatment with radium-223 dichloride (Ra). Ra is an α-emitting radionuclide that has been approved for use in the treatment of bone metastases that are secondary to castration resistant prostate cancer. PATIENTS AND METHODS:Six patients received two weight-based administrations of Ra 6 weeks apart. Activity excreted in the urine and faeces during the first 48 h following each treatment was assessed by direct counting of the excreta. During the same period the whole-body retention of Ra was also determined using a single probe counting system. The results of the excreta counting and the whole-body counting were compared to determine whether whole-body counting was a suitable surrogate for assessing excretion. Further whole-body retention counts were made at around 3, 4, 7 and 42 days following treatment. RESULTS:Patterns of excretion and retention of Ra varied significantly between patients, but were similar for each patient's pair of treatments. The cumulative maximum activity excreted in the initial 8-h period following the Ra administration was 2.6% that increased to 39% at 48 h. The median excreted activity at ~1 and 6 weeks after treatment was 70 and 86%, respectively. Skeletal retention of Ra at 6 weeks ranged from 11 to 60% of the administered activity.
URL
https://repository.icr.ac.uk/handle/internal/1229
Collections
  • Radiotherapy and Imaging
Licenseref URL
https://creativecommons.org/licenses/by/4.0
Version of record
10.1097/mnm.0000000000000783
Subject
Humans
Bone Neoplasms
Radium
Radioisotopes
Whole-Body Counting
Male
Prostatic Neoplasms, Castration-Resistant
Research team
Radioisotope Physics
Language
eng
Date accepted
2017-11-06
License start date
2018-02
Citation
Nuclear medicine communications, 2018, 39 (2), pp. 125 - 130

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.